Does the media prefer MNPR or AUPH?

In the previous week, Monopar Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Monopar Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Monopar Therapeutics' average media sentiment score of 0.37 beat Aurinia Pharmaceuticals' score of 0.30 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NVAX or MNPR?

In the previous week, Novavax had 24 more articles in the media than Monopar Therapeutics. MarketBeat recorded 29 mentions for Novavax and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.37 beat Novavax's score of 0.06 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 5 Very Negative mention(s) Neutral Monopar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BCRX or MNPR?

In the previous week, Monopar Therapeutics had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 5 mentions for Monopar Therapeutics and 4 mentions for BioCryst Pharmaceuticals. Monopar Therapeutics' average media sentiment score of 0.37 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, MNPR or PHVS?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is MNPR or PHVS more profitable?

Monopar Therapeutics' return on equity of -13.08% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% Pharvaris N/A -61.40% -56.00%

Does the media refer more to MNPR or PHVS?

In the previous week, Pharvaris had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Pharvaris and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.37 beat Pharvaris' score of 0.20 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MNPR or VIR more profitable?

Monopar Therapeutics' return on equity of -13.08% beat Vir Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% Vir Biotechnology N/A -29.99% -23.62%

Does the media refer more to MNPR or VIR?

In the previous week, Vir Biotechnology had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Vir Biotechnology and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.37 beat Vir Biotechnology's score of 0.09 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Monopar Therapeutics (MNPR) Competitors

$79.25 -4.73 (-5.63%)

As of 04:00 PM Eastern

Compare

MNPR vs. AUPH, NVAX, BCRX, PHVS, and VIR

Should you buy Monopar Therapeutics stock or one of its competitors? Monopar Therapeutics's main competitors and comparable companies include Aurinia Pharmaceuticals (AUPH), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Pharvaris (PHVS), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monopar Therapeutics compare to Aurinia Pharmaceuticals?

Monopar Therapeutics (NASDAQ:MNPR) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Monopar Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Monopar Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

Monopar Therapeutics presently has a consensus target price of $122.00, suggesting a potential upside of 45.27%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 8.92%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Monopar Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurinia Pharmaceuticals has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Aurinia Pharmaceuticals	$283.05M	7.62	$287.20M	$2.29	7.08

In the previous week, Monopar Therapeutics had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Monopar Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Monopar Therapeutics' average media sentiment score of 0.37 beat Aurinia Pharmaceuticals' score of 0.30 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aurinia Pharmaceuticals beats Monopar Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Novavax presently has a consensus price target of $14.00, suggesting a potential upside of 27.16%. Monopar Therapeutics has a consensus price target of $122.00, suggesting a potential upside of 45.27%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Novavax had 24 more articles in the media than Monopar Therapeutics. MarketBeat recorded 29 mentions for Novavax and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.37 beat Novavax's score of 0.06 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	5 Very Negative mention(s)	Neutral
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.0% of Novavax shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novavax has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.62	$440.30M	-$1.52	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

Novavax has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Monopar Therapeutics' return on equity of -13.08% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Summary

Monopar Therapeutics beats Novavax on 9 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Monopar Therapeutics (NASDAQ:MNPR) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Monopar Therapeutics had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 5 mentions for Monopar Therapeutics and 4 mentions for BioCryst Pharmaceuticals. Monopar Therapeutics' average media sentiment score of 0.37 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

BioCryst Pharmaceuticals presently has a consensus target price of $20.50, suggesting a potential upside of 147.29%. Monopar Therapeutics has a consensus target price of $122.00, suggesting a potential upside of 45.27%. Given BioCryst Pharmaceuticals' higher probable upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

BioCryst Pharmaceuticals has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.42	$263.86M	-$1.50	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Monopar Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Monopar Therapeutics' return on equity of -13.08% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Summary

BioCryst Pharmaceuticals and Monopar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Pharvaris?

Monopar Therapeutics (NASDAQ:MNPR) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Monopar Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, suggesting that its stock price is 346% less volatile than the broader market.

1.8% of Monopar Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Monopar Therapeutics currently has a consensus target price of $122.00, suggesting a potential upside of 45.27%. Pharvaris has a consensus target price of $58.60, suggesting a potential upside of 88.30%. Given Pharvaris' higher probable upside, analysts clearly believe Pharvaris is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Monopar Therapeutics' return on equity of -13.08% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Pharvaris	N/A	-61.40%	-56.00%

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

In the previous week, Pharvaris had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Pharvaris and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.37 beat Pharvaris' score of 0.20 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharvaris	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monopar Therapeutics beats Pharvaris on 9 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Vir Biotechnology?

Monopar Therapeutics (NASDAQ:MNPR) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Vir Biotechnology had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 11 mentions for Vir Biotechnology and 5 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.37 beat Vir Biotechnology's score of 0.09 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Vir Biotechnology	$68.56M	27.45	-$437.99M	-$1.86	N/A

Monopar Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

Monopar Therapeutics currently has a consensus target price of $122.00, suggesting a potential upside of 45.27%. Vir Biotechnology has a consensus target price of $21.86, suggesting a potential upside of 96.56%. Given Vir Biotechnology's higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Vir Biotechnology	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Monopar Therapeutics' return on equity of -13.08% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Vir Biotechnology	N/A	-29.99%	-23.62%

Summary

Monopar Therapeutics and Vir Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$546.72M	$3.89B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-37.54	13.85	274.54	26.18
Price / Sales	N/A	1,189.56	585.60	81.39
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	3.95	17.15	11.21	6.33
Net Income	-$13.72M	-$22.69M	$3.50B	$381.90M
7 Day Performance	4.46%	-0.94%	-0.68%	-1.27%
1 Month Performance	-27.53%	-9.50%	-5.29%	-4.19%
1 Year Performance	-19.33%	10.52%	4.62%	-0.21%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	2.9068 of 5 stars	$79.69 -5.1%	$122.00 +53.1%	-14.8%	$534.90M	N/A	N/A	22
AUPH Aurinia Pharmaceuticals	2.497 of 5 stars	$15.69 -0.2%	$17.67 +12.6%	+40.7%	$2.09B	$283.05M	6.85	128	News Coverage
NVAX Novavax	1.3358 of 5 stars	$11.32 -9.9%	$14.00 +23.7%	+23.7%	$2.07B	$1.12B	N/A	749	High Trading Volume
BCRX BioCryst Pharmaceuticals	2.3344 of 5 stars	$7.95 -1.9%	$20.50 +157.9%	+13.9%	$2.07B	$874.84M	N/A	435
PHVS Pharvaris	3.9122 of 5 stars	$31.12 +2.1%	$58.60 +88.3%	+35.4%	$1.99B	N/A	N/A	148	Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. AUPH, NVAX, BCRX, PHVS, and VIR

How does Monopar Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Monopar Therapeutics compare to Novavax?

Summary

How does Monopar Therapeutics compare to BioCryst Pharmaceuticals?

Summary

How does Monopar Therapeutics compare to Pharvaris?

Summary

How does Monopar Therapeutics compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. AUPH, NVAX, BCRX, PHVS, and VIR

How does Monopar Therapeutics compare to Aurinia Pharmaceuticals?

Do insiders and institutionals have more ownership in MNPR or AUPH?

Is MNPR or AUPH more profitable?

Which has more volatility & risk, MNPR or AUPH?

Do analysts prefer MNPR or AUPH?

Which has stronger earnings & valuation, MNPR or AUPH?

Does the media prefer MNPR or AUPH?

Summary

How does Monopar Therapeutics compare to Novavax?

Do analysts rate NVAX or MNPR?

Does the media favor NVAX or MNPR?

Do insiders & institutionals hold more shares of NVAX or MNPR?

Which has higher earnings & valuation, NVAX or MNPR?

Which has more risk & volatility, NVAX or MNPR?

Is NVAX or MNPR more profitable?

Summary

How does Monopar Therapeutics compare to BioCryst Pharmaceuticals?

Does the media prefer BCRX or MNPR?

Which has more volatility & risk, BCRX or MNPR?

Do analysts recommend BCRX or MNPR?

Which has preferable earnings and valuation, BCRX or MNPR?

Do institutionals and insiders have more ownership in BCRX or MNPR?

Is BCRX or MNPR more profitable?

Summary

How does Monopar Therapeutics compare to Pharvaris?

Which has more volatility and risk, MNPR or PHVS?

Do institutionals & insiders hold more shares of MNPR or PHVS?

Do analysts recommend MNPR or PHVS?

Is MNPR or PHVS more profitable?

Which has preferable valuation & earnings, MNPR or PHVS?

Does the media refer more to MNPR or PHVS?

Summary

How does Monopar Therapeutics compare to Vir Biotechnology?

Does the media refer more to MNPR or VIR?

Do insiders and institutionals hold more shares of MNPR or VIR?

Which has higher earnings & valuation, MNPR or VIR?

Which has more risk and volatility, MNPR or VIR?

Do analysts recommend MNPR or VIR?

Is MNPR or VIR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools